comparemela.com
Home
Live Updates
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes : comparemela.com
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
SUNNYVALE, Calif., Dec. 18, 2023 -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced...
Related Keywords
California ,
United States ,
Maryland ,
Japan ,
Japanese ,
Miranda Peto ,
David Mcclung ,
Peter Altman ,
Device Agency ,
Medicaid Services ,
Cardiamp Cell Therapy Program ,
Biocardia Inc ,
Exchange Commission ,
Globenewswire Inc ,
Centers For Medicare ,
Maryland Stem Cell Research Fund ,
Medical Device Agency ,
Failure Trial ,
Chief Executive ,
Cell Therapy ,
Stem Cell Research Fund ,
Autologous Cells ,
Heart Failure Trial ,
Looking Statements ,
Quarterly Reports ,
Investor Relations Email ,
Chief Financial Officer Email ,
Markets ,
comparemela.com © 2020. All Rights Reserved.